Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 11;226(10):1717-1720.
doi: 10.1093/infdis/jiac250.

Omicron Breakthrough Infection After Heterologous Prime-Boost Vaccination Induces a Vigorous Antibody Response

Augusto Varese  1 , Bianca Mazzitelli  1 , Fernando Erra Díaz  1 , María Victoria Kjolhede  1 , Diego Ojeda  2 , Alejandra Vellicce  3 , Penélope Arto  3 , Carla Cicero  3 , María Pascowsky  4 , Laura Figueras  5 , Bárbara Broese  5 , Rosa Dávila  6 , Rocío Zarlenga  1 , Federico Rivelli  1 , Camila Verruno  1 , Valeria Silenzi  1 , Ivana Beltrán  1 , Andrea Gamarnik  2 , Ana Ceballos  1 , Carlos Zala  5 , Adelina Badolati  4 , Jorge Geffner  1
Affiliations

Omicron Breakthrough Infection After Heterologous Prime-Boost Vaccination Induces a Vigorous Antibody Response

Augusto Varese et al. J Infect Dis. .

Abstract

Infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant is usually asymptomatic or mild and appears to be poorly immunogenic at least in unvaccinated individuals. Here, we found that health care workers vaccinated with 2 doses of Sputnik V and a booster dose of ChAdOx1 mount a vigorous neutralizing-antibody response after Omicron breakthrough infection.

Keywords: COVID-19; Omicron; SARS-CoV-2; neutralizing antibodies.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. All authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Figures

Figure 1.
Figure 1.
Analysis of antibody response induced by Omicron breakthrough infection. A, Titers of serum IgG anti-spike antibodies were analyzed by ELISA. The geometric means with 95% CIs are shown. B, Serum neutralizing titers against the ancestral variant B.1 and Omicron (BA.1) were analyzed using isolated variants. The geometric means with 95% CIs are shown. C, Paired B.1 and BA.1 neutralization titters for each sample. A and B, Kruskal-Wallis test and Dunn test for multiple comparisons were used. C, Wilcoxon pair-matched test was used. *P = .05, **P = .005, ***P = .0005, ****P = .0001. Dotted lines in panels A, B and C represents detection limits. Abbreviations: CI, confidence interval; ELISA, enzyme-linked immunosorbent assay; IgG, immunoglobulin G; nAbs, neutralizing antibodies.
See this image and copyright information in PMC

References

    1. Cameroni E, Bowen JE, Rosen LE, et al. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature 2022; 602:664–70. doi:10.1038/s41586-021-04386-2. - DOI - PMC - PubMed
    1. Cao Y, Wang J, Jian F, et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature 2022; 602:657–63. doi: 10.1038/s41586-021-04385-3. - DOI - PMC - PubMed
    1. Pajon R, Doria-Rose NA, Shen X, et al. SARS-CoV-2 Omicron variant neutralization after mRNA-1273 booster vaccination. N Engl J Med 2022; 386:1088–91. doi: 10.1056/NEJMc2119912. - DOI - PMC - PubMed
    1. Gruell H, Vanshylla K, Tober-Lau P, et al. mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. Nat Med 2022; 28:477–80. doi: 10.1038/s41591-021-01676-0. - DOI - PMC - PubMed
    1. Voto C, Baumeister E, Campos J, et al. COVID-19 situación de nuevas variantes SARS-CoV-2 en Argentina-SE8/2022 [in Spanish]. https://www.argentina.gob.ar/sites/default/files/2022/04/vigilancia_geno.... Accessed 9 June 2022.

Publication types

Supplementary concepts